drugset / Trial / NCT07388511

A Study of Elenestinib in Healthy Adult Female Participants

NCT07388511

Phase 1 Completed 20 enrolled Blueprint Medicines Corporation
NaSequentialOpen-labelOther

Summary

The main objectives of this study are to determine the effect of elenestinib on the pharmacokinetic parameters (how the drug is absorbed, distributed, and processed by the body) of midazolam, and to determine the effect of elenestinib on the pharmacokinetic parameters of levonorgestrel/ethinyl estradiol, when given as a combined oral contraceptive. Healthy adult participants will receive midazolam and levonorgestrel/ethinyl estradiol with and without elenestinib and have blood samples taken.

Timeline

Start
2026-02-05
Primary completion
2026-04-02
Completion
2026-04-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Elenestinib Small molecule
Subject Levonorgestrel Small molecule
Subject Midazolam Small molecule
Subject ethinyl estradiol Small molecule

Indications

No indication recorded.